Truvestments Capital LLC Purchases 986 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Truvestments Capital LLC raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1,825.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,040 shares of the medical equipment provider’s stock after acquiring an additional 986 shares during the period. Truvestments Capital LLC’s holdings in Intuitive Surgical were worth $415,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of ISRG. Provence Wealth Management Group bought a new stake in Intuitive Surgical during the fourth quarter worth approximately $276,000. Portside Wealth Group LLC increased its position in shares of Intuitive Surgical by 8.2% during the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in Intuitive Surgical by 58.0% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after buying an additional 3,054 shares during the period. Public Employees Retirement System of Ohio lifted its position in Intuitive Surgical by 5.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after buying an additional 9,869 shares during the last quarter. Finally, HCR Wealth Advisors boosted its stake in Intuitive Surgical by 26.3% during the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after buying an additional 217 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, SVP Mark Brosius sold 175 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $389.16, for a total value of $68,103.00. Following the sale, the senior vice president now directly owns 883 shares in the company, valued at approximately $343,628.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Mark Brosius sold 175 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the transaction, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Myriam Curet sold 2,818 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $1,291,010.34. Following the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. The disclosure for this sale can be found here. Insiders sold 13,358 shares of company stock worth $5,592,694 in the last three months. 0.90% of the stock is owned by insiders.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG traded up $4.56 during trading hours on Friday, hitting $441.30. The company’s stock had a trading volume of 1,196,597 shares, compared to its average volume of 1,795,967. The firm’s fifty day moving average price is $427.82 and its 200 day moving average price is $398.55. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $468.78. The company has a market capitalization of $156.82 billion, a price-to-earnings ratio of 79.66, a P/E/G ratio of 4.81 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the previous year, the firm posted $1.18 earnings per share. Intuitive Surgical’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ISRG shares. Piper Sandler increased their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. BTIG Research raised their price objective on shares of Intuitive Surgical from $451.00 to $459.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a research note on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Evercore ISI reduced their price target on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a report on Friday, July 19th. Finally, Robert W. Baird boosted their price objective on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $438.74.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.